Sadamoto Zenda

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 218 citations

Drug Safety, Chemotherapy-induced Nausea, Pharmacology +7

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

Shuichi Hironaka, Sadamoto Zenda, Narikazu Boku et al. · Gastric Cancer · 2006 · 145 citations · Full text

Gastrointestinal Oncology, Recurrent Gastric Cancer, Medicine +8

Proton Beam Therapy for Unresectable Malignancies of the Nasal Cavity and Paranasal Sinuses

Sadamoto Zenda, Ryosuke Kohno, Mitsuhiko Kawashima et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 94 citations

Proton Beam Therapy, Radiation Medicine, Radiation Therapy +8

Analysis of dose–volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer

Hirofumi Asakura, Takayuki Hashimoto, Sadamoto Zenda et al. · Radiotherapy and Oncology · 2010 · 81 citations

Radiation Medicine, Dose–volume Histogram Parameters, Health Sciences +9

Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Susumu Okano, Takashi Yoshino, M Fujii et al. · Japanese Journal of Clinical Oncology · 2013 · 67 citations · Full text